The European Commission has given conditional approval next-generation stem cell therapy to the product known as Holoclar to be used in burns to the eyes.

Holoclar is a new cell therapy that is produced using corneal epithelial cells from the patient’s healthy eye, which are then expanded and transplanted in the damaged eye (NatureBiotechnology 33; 224-225,2015).